Notably, MET amplification has been identified as a driver of MPNST progression in NF1, and tumors with this alteration exhibit strong sensitivity to the MET inhibitor capmatinib, especially when combined with MEK inhibition [123]. Here, MET is linked to malignant peripheral nerve sheath tumor.